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Objective: To report the attitudes of community pharmacists in Kabul, Afghanistan, concerning the quality and
price of locally manufactured medicines.
Methods: A cross-sectional descriptive study, involving a sample of 198 community pharmacists was conducted in
Kabul city.
Results: With a response rate of 100%, most of the respondents 70.7% had 11–20 years experience working as a
pharmacist. About 84.3% of the pharmacists dispensed imported generic medicines from Pakistan, Iran, India, and
the UAE. Only 15.7% of pharmacists were dispensing locally produced generics from Ariana (i.e. a local
pharmaceutical manufacturer). Exactly half of the pharmacists 50.0% reported that locally produced generics were
equally safe and efficacious as the imported generics, while 70.7% of the respondents believed that the local
manufacturers of generic products had reliable logistics and supply systems. However, 80.8% of respondents
expressed concerns regarding their own credibility when stocking the medicines. Consequently, 80.3% of the
sample only stocked well-advertised domestic generics, which were likely to be seen by consumers as more
credible alternatives. Most of the respondents 82.8% were confident that the locally manufactured generics were
cheaper than imported generics. Interestingly, 80.8% of the respondents favoured the establishment of a national
brand substitution policy. Furthermore, 90.4% of the respondents believed that it was the responsibility of the
Afghan regulatory authorities to educate pharmacists on the quality of domestic generics.
Conclusion: Although community pharmacists had a positive attitude towards the quality and affordability of
locally manufactured medicines, due to lack of resources most of their medicines are imported. Despite their
positivity towards the quality and price of generics, the community pharmacists only dispense them to a minimal
degree, because of low local production levels among other reasons. The findings call for improvements in the
local pharmaceutical industry in order to substitute imported medicines with local generics. The government
must take firm steps to formulate and reinforce pharmaceutical pricing and brand substitution policies to help in
controlling healthcare costs. Further research, especially a countrywide survey, is required.
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Prior to 1979, Afghanistan had sufficient domestic
pharmaceutical manufacturing to meet local demand, as
well as export capacity [1,2]. Due to decades of conflict,
the pharmaceutical industry collapsed and remained
“understudied” [3], being one of the least developed
industrial sectors in the world, functioning with many
weaknesses and in a disorganised manner [4]. According to
WHO, the overall pharmaceutical situation in Afghanistan
has deteriorated because health infrastructure, machinery,
laboratories and buildings have been seriously damaged or
destroyed [5].
However, despite these deficiencies, after 2001 a few
multinational pharmaceutical companies started importing
medicines to Afghanistan and 14 small and medium-sized
privately owned pharmaceutical manufacturing com-
panies have contributed to the growth of the industry
[6]. Nonetheless, according to a recent assessment of
domestic pharmaceutical manufacturing capacity in
Afghanistan, the sector is facing a number of critical issues
[1]. For example, no licensing authority that issues Good
Distribution Practices (GDP) licenses exists and there are
no national guidelines on GDP [2]. The medicine supply
system is critically under-regulated with weak provincial
management leading to an erratic supply situation [4].
There is no national Good Manufacturing Practice
(GMP) or Adverse Drug Reaction (ADR) guidelines,
and a medication error reporting system is lacking. In
addition a pharmacovigilance system has not yet been
introduced [7]. Due to a lack of sufficient budget, human
resources and infrastructure, the implementation of
policies, legislation, and regulations is slow.
To address these outstanding issues in the pharmaceutical
sector, the Ministry of Public Health (MOPH) has devel-
oped a strategic plan for 2011–2015 [8]. One of the objec-
tives of this strategic plan is to establish and implement a
health governance system to ensure transparency and
efficiency in pharmaceutical supply chain management, and
increase local pharmaceutical production capacity [8].
Under this objective, the government has shown its com-
mitment to improve the production of locally manufactured
generic medicines. They have recognised that soaring
medicine costs could be controlled by promoting the use of
affordable, safe and effective generic medicines instead of
their more expensive branded equivalents [9,10].
A generic medicine is a pharmaceutical product, usually
intended to be interchangeable with an innovator product,
that is manufactured without a license from the innovator
company, and is marketed after the patent or any other
exclusive rights belonging to the innovator company
have expired [11]. Stringent quality measures must
be undertaken and the generic medicine must meet
the standards of the originator brand in order to be
considered safe [12,13].Due to lower prices, generic medicines can yield signifi-
cant healthcare cost savings and these savings can be used
to subsidise expensive novel medicines and support
pharmaceutical research and development [14]. The first
low-cost generic medicine program in the United States,
introduced in September 2006 by Wal-Mart, offered a
limited number of generic medicines at a cost of US$4 for a
month’s supply of each drug [15]. Similarly, in the UK, the
government has provided strong incentives to promote
generic prescription and use [14]. Many other governments
have also advocated shifting to lower cost generic
medications in order to improve affordability, reduce
healthcare spending, and promote better adherence to
drug regimens [16-18]. In France, controlling pharma-
ceutical expenditure has been a policy priority for
many years and policies favouring generic medications
have featured prominently [19]. Direct price control
policies are a common phenomenon, even in generic
medicine markets, France being just one example. The
French authorities stipulate that the price of a generic
medicine must be 30% lower than that of equivalent
branded medicines [20]. Similarly, the Danish medicines
agency introduced “Medicine Profile,” a database for both
general practitioners and patients to check their medicines
and to compare the price of innovator medicines with
generic alternatives [21]. The Danish generic medicine
policy gave rise to conditions favouring the development
of a low-price high-volume generic medicine market [21].
In Portugal, pro-generic medicine media campaigns were
undertaken resulting in increased demand [21].
Where a favourable market for generic medicines has
been developed, health care has become significantly more
affordable and its universal coverage more sustainable [21].
Generic medicines allow governments to exercise greater
fiscal control over their pharmaceutical expenditure
because generic medicines should ideally be as safe, and of
the same quality and therapeutic efficacy, as their branded
equivalent medicines [21]. Therefore, efforts should be
made to extend generic medicine public awareness
programs and advocacy activities to include more detailed
information, so that patients have a greater understanding
of brand substitution practices. It is equally critical that
physicians and pharmacists have an accurate understanding
of brand substitution, and that they provide accurate
information to patients [22].
The affordability of prescription medicines is one of
the most pressing public health issues in the United
States. According to at least one study, many patients
self-administer less than their prescribed dose so as to
make medications last longer, or fail to fill prescriptions
because of the cost [15]. Consequently, brand substitution
is supported by health authorities in many countries
throughout the world because it provides cheaper alterna-
tives to innovator medicines [23]. However, according to
Table 1 Respondent demographics
Demographic Information Frequency
(%)
Gender Male 196 (99.0)
Female 2 (1.0)
Age Under 30 15 (7.6)
30–40 46 (23.2)
41–50 127 (64.1)
Over 50 10 (5)
Year of Graduation Before 1980 4 (2)
1981–1990 36 (18.2)
1991–2000 135 (68.2)
After 2001 23 (11.6)
Years of practice in community pharmacy Less than 10 44 (22.2)
11–20 140 (70.7)
21–30 14 (7.1)
Country of Graduation Afghanistan 188 (94.9)
Foreign 10 (5.1)
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prescribing policies exists in Afghanistan and there is a lack
of research in this area. Pharmacists play a pivotal role and
as healthcare providers, therefore it is imperative that they
know about the price and quality of generic medicines.
Additionally, it is crucial that policy makers understand
these matters in order to establish a sound generic
medicine policy leading to substantial savings in health
care expenditure and improving access to essential
medicines in the country [24,25].
Therefore, in this study, we aimed to explore the attitudes
of community pharmacists in Kabul regarding the quality
and price of locally manufactured generic medicines.
Methods
This cross-sectional study relied on a convenience sam-
ple of community pharmacists from Kabul, Afghanistan.
Prior to conducting the study, ethical approval was
granted by the local Institutional Review Board (IRB).
Over a four-month period, from March–June 2013, re-
spondents were approached and asked to participate in
the study. The questionnaire had previously been used in
Penang, Malaysia [26], and approval for use of the ques-
tionnaire in the present study was granted by the author.
One question was added in order to assess the community
pharmacists’ attitudes regarding the affordability of do-
mestic generic medicines. The draft questionnaire was
reviewed for accuracy and validity, then translated and
back-translated into Dari (Farsi). Minor revisions were
made to the translated questionnaire after initial pilot
testing.
The final questionnaire that was administered to
participants was in three sections. The first section
collected participants’ demographic information with the
help of five questions. The second section inquired about
the pharmaceutical companies (Abbot, GSK, Getz, Julphar,
Exir, Gracure and Ariana), from which the pharmacists
were sourcing their generic medicine stocks. The six
international companies and one local company (Ariana)
were included because of their popularity, medicine stocks
and the retailers’ inclination towards procurement from
them. From the list of seven companies, the respondents
were asked to identity from which they obtained their
stocks. In the third section, eleven questions asked about
the community pharmacists’ views on issues concerning
locally manufactured generic medicines. In this section of
the questionnaire the respondents were asked to indicate
their responses on a five-point Likert scale (1 = strongly
agree, 2 = agree, 3 = neutral, 4 = disagree, 5 = strongly
disagree).
A total of 198 community pharmacists were approached
for participation in this study by visiting a range of public
and private hospitals, clinics, and pharmacies (i.e. medical
outlets) across Kabul. Participation was voluntary and theanonymity of the respondents was preserved. There was
no part of the questionnaire for the recording of identifying
personal information. After the completed questionnaires
were collected, the data was analysed with SPSS 16.0
for descriptive analysis, using frequency analysis and
cross-tabulation to examine the data characteristics
and to summarise the overall results.
Results
Demographic information of the respondents
The basic demographic information of the respondents
is summarised in Table 1. All of the 198 participants
took part in the survey, where 70.7% had 11–20 years of
pharmacy practice in the community. The majority of
respondents 99% were male and 87.3% of the respon-
dents were aged 30–50 years. Experienced community
pharmacists were more inclined to know about generic
medicine and dispense it. Among all the interviewees,
94.9% had graduated from local universities.
Findings on the stocking and dispensing of generic
medicines
When assessing the community pharmacists’ generic
medicine stocking and dispensing behaviour, it was
found that the majority of respondents 84.3% were
dispensing imported generic medicines from Pakistan,
Iran, India, and the UAE (Table 2). Ariana, one of
several local Afghan generic pharmaceutical companies,
was used by only 15.7% of pharmacists. Nearly half
45.9% of the imported generic medicines dispensed by
pharmacists were from Abbot 10.1%, GSK 14.1%, and
Getz (a Pakistani pharmaceutical manufacturer, 21.7%.
Table 2 Pharmaceutical companies where pharmacists
purchase their generic medicine
Pharmaceutical Company Country of Origin Frequency %
Abbot Pakistan 20 (10.1)
Julphar UAE 18 (9.1)
GSK Pakistan 28 (14.1)
Exir Iran 46 (23.2)
Getz Pakistan 43 (21.7)
Gracure India 12 (6.1)
Ariana Afghanistan 31 (15.7)
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by 23.2% of the pharmacists, showing that this company
has a good market in Kabul.
Community pharmacists’ attitudes towards the quality
and price of locally manufactured generic medicines
When respondents were asked about their views of the
quality and price of locally produced generic medicines,
50.0% indicated that the locally produced generics were as
safe and efficacious as imported generics. Furthermore,
70.7% of the respondents believed that local generic
manufacturers had reliable logistics and supply systems.
Notwithstanding, only half of the respondents 50.0%Table 3 Community pharmacists’ attitude towards the quality
Question Survey questions/Statement Fr
1
1 Locally manufactured generics are equal in their quality
compared to the imported generics.
71
2 Locally manufactured generics are equal in their safety
and efficacy compared to the imported generic.
24
3 Manufacturers of local generic products have a reliable
logistic and supply system.
56
4 I prefer to stock and dispense locally manufactured generics
because the companies provide good bonus scheme
compared to suppliers importing them.
46
5 Credibility of the generic manufactures/suppliers are
my concern when stocking medicines in my pharmacy.
10
6 I will only stock locally manufactured product which is
well advertised through medical representatives and
medicine related references.
11
7 Imported generics need to pass more stringent approval
process compared with locally manufactured ones.
98
8 Locally manufactured generics are cheaper compared
to imported generics.
12
9 Locally manufactured generics are affordable to be
purchased in comparison to imported generics.
55
10 I believe we need to establish brand substitution policy
in Afghanistan.
13
11 The Afghan Drug Regulatory Authorities need to convince
pharmacists that registered locally manufactured generics
are of high quality and standards.
13preferred to stock locally manufactured generics even
though the local manufacturers provided better bonus
schemes than the pharmaceutical importers. The majority
of respondents 82.8% also indicated having concerns about
the credibility of manufacturers/suppliers when stocking
generic medicines. In addition, most of the respondents
80.3% reported that they would only stock locally manufac-
tured generics that had been well advertised in both the
general and medical/professional media (Table 3).
In the opinion of most of the respondents 87.4%
imported generics are required to pass through more strin-
gent approval processes, as their origin is not known. Also,
the majority of respondents 82.8% agreed that the locally
manufactured generics were cheaper than the imported
generics. Just over half 58.1% of the respondents believed
that local generics are more affordable than imported
generics. Interestingly, 80.8% of the respondents agreed that
Afghanistan should establish a national brand substitution
policy and further, the majority of the respondents 90.4%
indicated that the Afghan drug regulatory authorities need
to convince pharmacists that registered locally manufac-
tured generics are of high quality and standards.
Discussion
In Afghanistan, as in many other low-income post-conflict
settings, there are more imported medicines than locallyand prices of locally manufactured generic medicines
equency (%)
2 3 4 5 No answer
(35.9) 23 (11.6) (0) 78 (39.4) 22 (11.1) 4 (2.0)
(12.1) 75 (37.9) 4 (2) 83 (41.9) 8 (4) 4 (2.0)
(28.3) 84 (42.4) 16 (8.1) 28 (14.1) 9 (4.5) 5 (2.5)
(23.2) 53 (26.8) 6 (3) 77 (38.9) 11 (5.6) 5 (2.5)
3 (52) 61 (30.8) 3 (1.5) 23 (11.6) 2 (1) 6 (3.0)
7 (59.1) 42 (21.2) 6 (3) 20 (10.1) 8 (4) 5 (2.5)
(49.5) 75 (37.9) 9 (4.5) 9 (4.5) 3 (1.5) 4 (2.0)
1 (61.1) 43 (21.7) 5 (2.5) 19 (9.6) 6 (3) 4 (2.0)
(27.8) 60 (30.3) 6 (3) 21 (10.6) 51 (25.8) 5 (2.5)
2 (66.7) 28 (14.1) 7 (3.5) 16 (8.1) 10 (5.1) 5 (2.5)
3 (67.2) 46 (23.2) 8 (4) 4 (2) 2 (1) 5 (2.5)
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concerns regarding quality and price. The Afghan
pharmaceutical market is largely dependent on privately
imported medicines due to a lack of local pharmaceutical
companies and infrastructure. Afghanistan imports over
95% of its medicines from other countries [27]. In the
current study, we found that majority of the respondents
chose to stock imported generic medicines (Table 2); there-
fore, our findings are consistent with those of Paterson [6].
Low-income countries are commonly believed to have
poor quality health services [28] and Afghanistan is no
exception. Due to three decades of conflict, the situation
has deteriorated. The Afghan pharmaceutical and health
care system, including the supply of medicines, remains
largely ad hoc and disorganised, with little production
capacity of its own. Many actors, including government
ministries, non-governmental organisations, foreign
mission hospitals, and the private sector make up the
system. Each of these actors is largely independent of
the others and is responsible for their own procurement,
logistics, supplies, and distribution networks [4,6]. The
General Directorate for Pharmaceutical Affairs (GDPA),
in addition to regulating the local pharmaceutical industry,
is charged with the responsibility of ensuring the safety
and quality of imported medicines [2]. However, for
multiple reasons, including a lack of funding, limited
human resources, and a lack of clear policy direction,
the GDPA is sorely limited in its capacity to execute
this monitoring role.
As mentioned earlier, more than half of the respondents
felt that locally produced generics were as safe and as
efficacious as imported generic medicines. This finding is
consistent with international studies, which also find
that local generics are perceived to be similarly safe
and effective compared to imported generics [26].
However, the quality of imported medicines is often
questioned by the public, with low quality, spurious,
counterfeit, and expired medicines entering the country
through legal loopholes or otherwise smuggled into the
country. Furthermore, much of the patient population is
illiterate and naive about pharmaceutical manufacturing
and expiry dates. Therefore, to maintain the trust of both
community pharmacists and patients alike, the Afghan
regulatory authorities should implement more stringent
regulation, including higher standards of quality manage-
ment, guaranteeing the quality of imported generic
medicines by performing quality control laboratory
exams, and ensure good distribution practices. This
argument is not without precedence, a Malaysian study
similarly finding support for imported generics needing to
pass a more stringent approval processes [26]. However,
in many post-conflict settings, government regulations
exist only on paper or serve only to benefit corrupt
or ineffective government officials [29].The medicines available in Afghanistan tend to be of
poor quality. This is partially attributable to the scarcity
of resources available to the National Medicines and
Food Board (NMFB) to properly control and assess the
quality of medicines. Another reason underlying the
poor quality of available medicines concerns the role of
importers and distributors. While every effort is made to
import medicines which should be cheap and affordable,
as with any private enterprise it is imperative to make a
profit, and handsome profits can be made by subverting
the regulatory system [30]. Consequently, alternative and
black market supply channels allow for the introduction of
expired and otherwise cheaper poor quality generics to
enter the market. In addition, the practice of counterfeiting
medications is not unheard of in Afghanistan. Therefore,
the use of local generic medicines can be enhanced
by improving their quality, instituting appropriate brand
substitution policies, and by educating consumers [29,31].
This is clearly essential, since the economic goal of cost
containment by generic substitution is worthless if it
causes death instead of cure [32].
In the current study, most of the respondents recom-
mended that the Afghan drug regulatory authorities should
be working to convince pharmacists that registered, locally
manufactured generics are of as high a quality as most
imported medicines and are manufactured in compliance
with international standards. In addition, more than
half of the participating pharmacists agreed that domestic
generics are cheaper than imported generics. Similarly,
the Malaysian study also found that domestic generics
were cheaper than their imported counterparts [26].
Imported medicines tend to be more expensive due
to various taxes, tariffs, and other duties along the
procurement chain. Brand substitution is an effective
cost-containment solution to this problem.
Healthcare authorities throughout the world encourage
the practice of generic substitutions [33], and Afghanistan is
no exception. Therefore, in this study, most of the respon-
dents strongly supported the establishment of a national
brand substitution policy in Afghanistan. These findings are
almost identical to those of Hassali et al. [26].
Brand substitution has become common practice in
the United States since the late 1970s [13]. Widespread
brand substitution of outpatient prescription drugs has
saved approximately US$8.8 billion, or approximately
11% of the pharmaceutical budget for adults, in the United
States each year [34,35]. Similarly, brand substitution by
pharmacists is standard practice in UK hospitals and is
being proposed for implementation in primary care [13].
Although 83% of community or primary care physicians
in the UK already write prescriptions for generic medi-
cines [25], substituting more expensive generic brands
with even less expensive generic brands might still result
in further savings. Therefore, efforts to promote brand
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point of prescription, the treating physician [25]. As the
earlier Malaysian study revealed, the desire to maintain a
high profit margin is one of the main reasons that com-
munity pharmacists practice brand substitution [29,36].
Brand substitution is a collaborative act, therefore the
pharmacists and patients must be informed and trained
[36] since, at the dispensing point, the pharmacist plays
an important role in helping patients choose between
branded or generic medicines [15,23,25]. Therefore,
the undergraduate pharmacy and medical curricula may
need to be updated and adapted especially in the
regulatory and quality control aspects of generic medi-
cines, and further bioequivalency requirements must be
applied to the registration and production of generic
medicines [26,37].
From this study, it is clear that community pharmacists
in Kabul city have a positive attitude towards the
quality and price of locally manufactured medicines,
the implementation of generic substitution policy, and
the application of stringent quality control systems.
This positive attitude is an opportunity for the health
authorities to embark on development and reinforcement
of generic medicine policy in Afghanistan. This can lead
to improved access to quality assured locally manufac-
tured medicine and savings on healthcare costs both for
patient and government.
Limitations of the study
The study has the limitations inherent in most survey-type
studies, for example a hardcopy questionnaire was used for
data collection, meaning there is a chance that subjects
refer to the internet or other educational resources to
answer the knowledge-based questions [38]. Further, there
is a possibility of a social desirability response bias on the
attitude issues, where the interviewees might be inclined to
provide more favourable responses toward generic medi-
cine [38,39]. Finally, this study was conducted in Kabul city
focusing on community pharmacists; therefore, the sample
and results may not be representative of the attitudes of all
community pharmacists and all cities in the country.
Conclusion
The findings of the current study indicate a positive
attitude among community pharmacists towards locally
manufactured medicines. Although they appeared to
believe that quality generic medicines are affordable and
would result in significant cost savings, due to lack of
pharmaceutical manufacturing resources most medicines
are imported. Additionally, the community pharmacists
generally expressed positive attitudes towards the quality
and price of locally manufactured generics, but dispense
them in minimal amounts, due to a low level of local
production. This suggests that domestic pharmaceuticalcompanies should be empowered to produce substitutes
for imported medicines. Further, now may be the ideal
time for the government to embark on a process of
formulating explicit pharmaceutical pricing and brand
substitution policies in order to exercise greater control
over health care costs.
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